#United States #Karyopharm #XPOVIO #Newton #Lori Macomber

Karyopharm Therapeutics Appoints Lori Macomber as New Chief Financial Officer

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an innovative commercial-stage pharmaceutical company known for its groundbreaking work in cancer therapies, has announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer, and Treasurer. Her new role, effective January 3, 2025, places her at the helm of the company’s financial strategy and operations, guiding them on a path toward profitability and growth.

Richard Paulson, President and CEO of Karyopharm, expressed enthusiasm over Macomber's hiring, stating that her impressive background in financial management and operations is essential for the company's future objectives. Commenting on her new position, Macomber noted, “I am thrilled to join Karyopharm at this crucial juncture as we advance our pipeline of innovative therapies and look forward to working with the leadership team to contribute to the Company's success.”

A Wealth of Experience

With over two decades in the life sciences sector, Macomber brings a wealth of experience to Karyopharm. Her career has encompassed various leadership roles, primarily focusing on financial strategy and management across companies of diverse sizes—from startups to large Fortune 500 firms. Previously, she held the CFO position at Legend Biotech Corporation, a publicly traded biopharmaceutical company, where she significantly influenced financial operations and strategic decisions.

Prior to her work at Legend Biotech, Macomber's career journey included influential roles at well-known corporations such as Ametek PDS, Cello Health, Eli Lilly, and Pfizer. She holds a Bachelor of Science degree in Accounting from Pennsylvania State University and is a Certified Public Accountant, making her an invaluable asset for Karyopharm's ongoing development.

Strategic Goals and Financial Incentives

As part of her onboarding process, Karyopharm granted Macomber a substantial inducement award comprising a stock option to purchase 650,000 shares and 160,000 restricted stock units. This move aligns her personal financial incentives with the company’s growth objectives, ensuring stakeholders can benefit from the enhanced leadership direction.

The stock options will be vested over four years, motivating Macomber to focus on sustainable company growth and effective expense management while advocating for the development of the company's flagship product, XPOVIO® (selinexor) among others in the clinical pipeline.

Driving Revenue Growth

Under Macomber’s financial leadership, Karyopharm aims to grow XPOVIO's revenue and streamline operational costs. The drug is recognized as a first-in-class oral exportin 1 (XPO1) inhibitor and has received regulatory approval for various oncology indications.

Karyopharm’s focus is set on expanding its pipeline targeting high unmet medical needs which includes critical cancers like multiple myeloma and diffuse large B-cell lymphoma. Macomber's broad experience with collaboration partnerships, business development, and licensing deals is expected to foster strategic alliances that can propel these initiatives further.

An Integrated Approach to Care

Karyopharm Therapeutics is rooted in the belief that patients with cancer exhibit extraordinary resilience and strength. This foundation underpins its mission to advance innovative treatments that address the fundamental mechanisms of cancer. The appointment of Lori Macomber symbolizes a strategic enhancement to its leadership team in a time when the demand for effective cancer therapies is ever-growing.

As Karyopharm continues to push boundaries in therapeutic developments, Macomber's strategic financial insights will be pivotal in navigating the complexities of the pharmaceutical landscape. The commitment to improving patient outcomes and advancing clinical trials under her guidance is anticipated to yield significant results as the company moves forward.

For more information about Karyopharm’s mission and pipeline, you can visit www.karyopharm.com and connect with them on social media platforms.

Conclusion

In summary, Lori Macomber's appointment as CFO represents a strategic step for Karyopharm Therapeutics, aiming to align financial goals with corporate growth and innovation in the fight against cancer. As the company gears up for a promising future with Macomber at the helm of its financial strategy, the expectations from healthcare stakeholders and investors are high, placing the focus firmly on enhanced financial performance, sustained operational efficiency, and above all, impactful patient care.